September 7, 2022 11:39 AM EDTUpdated September 8, 02:31 PM
News Briefing

Io­n­is, As­traZeneca go­ing to FDA with PhI­II da­ta in hand; Glaukos touts dou­ble PhI­II win in eye im­plant

Paul Schloesser

Associate Editor

Kyle LaHucik

Senior Reporter

Tyler Patchen

News Reporter

Io­n­is and As­traZeneca are hop­ing its lat­est re­sults net an FDA ap­proval.

The two com­pa­nies pre­sent­ed their lat­est Phase III re­sults …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

A service from the Financial Times